European Commission within a framework of Horizon 2020 programme “Dedicated support to the biotechnology SMEs closing the gap from lab to market” awarded Latima with a grant for cancer virotherapy medicine commercialization in the EU markets. Latima is part of Rigvir holding, a group of companies, which develops and promotes cancer virotherapy worldwide.
Horizon 2020 is the biggest EU Research and Innovation programme ever with nearly 80 billion euros of funding available over 7 years (2014 to 2020) in addition to the private investment that this money will attract. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. The Horizon 2020 program is administered by the European Commission in Brussels and can be used by participants from all over the European Union.
Kārlis Urbāns, Finance director of Rigvir holding: “There are millions of cancer patients around the world who are in need of this unique cancer medicine. At the moment Rigvir is approved in 3 countries so far, however other patients can get virotherapy with Rigvir via medical tourism. I hope that this grant will make cancer virotherapy more available for everyone who would benefit from it. Cancer patients deserve this safe, effective and humane cancer treatment”.